We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen is hoping a Delaware judge will be more agreeable than a California court as it sues Hospira to slow the biosimilar maker from marketing its challenger to Epogen.